SLAM
PCVX icon

Swiss Life Asset Management’s Vaxcyte PCVX Stock Holding History

Swiss Life Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Buy
7,818
+935
+14% +$50.8K ﹤0.01% 1014
2026
Q1 		$400K Buy
6,883
+1,484
+27% +$80.6K ﹤0.01% 969
2025
Q4 		$249K Buy
+5,399
New +$241K ﹤0.01% 1134

Other funds holding PCVX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Swiss Life Asset Management's PCVX Position: Q2 2026 in Review

Swiss Life Asset Management increased its Vaxcyte (PCVX) stake by 14% in Q2 2026, buying an estimated $50.8K and bringing the position to 7,818 shares worth $454K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Swiss Life Asset Management first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Swiss Life Asset Management held 7,818 shares of Vaxcyte worth $454K as of Q2 2026.
  • Swiss Life Asset Management bought 935 Vaxcyte shares in Q2 2026, an estimated $50.8K.
  • Vaxcyte made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1014 holding.
  • Swiss Life Asset Management first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.